Trial Profile

A first-in-human, phase 1 trial for safety and efficacy of IKS03 a CD19-targeted antibody drug conjugates (ADCs) in treatment of B-cell cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IKS 03 (Primary)
Indications B-cell lymphoma; Duodenal cancer; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Iksuda Therapeutics

Most Recent Events

30 May 2025 According to an Iksuda Therapeutics media release, company announces first patient successfully dosed in this study.
12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition
06 Sep 2023 Planned End Date changed from 1 Jul 2027 to 1 Sep 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com